These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 16896003

  • 1. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology Group.
    J Clin Oncol; 2006 Sep 01; 24(25):4143-9. PubMed ID: 16896003
    [Abstract] [Full Text] [Related]

  • 2. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
    Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.
    Blood; 2003 Sep 01; 102(5):1606-12. PubMed ID: 12738671
    [Abstract] [Full Text] [Related]

  • 3. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
    Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.
    J Clin Oncol; 2013 Jan 20; 31(3):314-20. PubMed ID: 23233710
    [Abstract] [Full Text] [Related]

  • 4. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP.
    J Clin Oncol; 2010 Jun 20; 28(18):3035-41. PubMed ID: 20458031
    [Abstract] [Full Text] [Related]

  • 5. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.
    J Clin Oncol; 2005 Nov 20; 23(33):8447-52. PubMed ID: 16230674
    [Abstract] [Full Text] [Related]

  • 6. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
    Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.
    J Clin Oncol; 2018 Mar 01; 36(7):697-703. PubMed ID: 29356608
    [Abstract] [Full Text] [Related]

  • 7. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
    Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5696-704. PubMed ID: 16110029
    [Abstract] [Full Text] [Related]

  • 8. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
    Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.
    Clin Cancer Res; 2013 Dec 01; 19(23):6624-32. PubMed ID: 24130072
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.
    J Clin Oncol; 2004 Jul 01; 22(13):2654-61. PubMed ID: 15159414
    [Abstract] [Full Text] [Related]

  • 10. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA.
    Clin Lymphoma Myeloma; 2009 Jun 01; 9(3):223-8. PubMed ID: 19525191
    [Abstract] [Full Text] [Related]

  • 11. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 12. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
    Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW.
    Lancet Haematol; 2018 Mar 01; 5(3):e102-e108. PubMed ID: 29396094
    [Abstract] [Full Text] [Related]

  • 13. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
    Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI.
    J Clin Oncol; 2001 Feb 01; 19(3):750-5. PubMed ID: 11157027
    [Abstract] [Full Text] [Related]

  • 14. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
    Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW.
    J Clin Oncol; 2015 May 01; 33(13):1482-90. PubMed ID: 25823738
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI.
    J Clin Oncol; 2001 Jan 15; 19(2):389-97. PubMed ID: 11208830
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N, Kodama F, Oshima R, Hashimoto C, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y.
    Leuk Lymphoma; 2006 Jun 15; 47(6):1041-7. PubMed ID: 16840195
    [Abstract] [Full Text] [Related]

  • 17. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P.
    Leuk Lymphoma; 2006 Jul 15; 47(7):1306-14. PubMed ID: 16923561
    [Abstract] [Full Text] [Related]

  • 18. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul 15; 4(7):536-8. PubMed ID: 17147240
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
    Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, Sill H.
    Eur J Haematol; 2002 Jul 15; 69(1):21-6. PubMed ID: 12270058
    [Abstract] [Full Text] [Related]

  • 20. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S.
    Clin Cancer Res; 2007 Oct 01; 13(19):5784-9. PubMed ID: 17908969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.